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Objective: To compare the safety and efﬁcacy of a single intra-articular (IA) injection of a new cross-linked
hyaluronic acid product, Gel-200, with phosphate buffered saline (PBS, control) in a multi-center
randomized controlled trial in patients with symptomatic osteoarthritis (OA) of the knee.
Design: Patients were randomized 2:1 to receive a single injection of Gel-200 or PBS, after joint aspi-
ration. The primary measure of effectiveness was Western Ontario and McMaster Universities Osteoar-
thritis Index (WOMAC) pain subscores by 100-mm Visual Analog Scale (VAS); secondary outcomes
included: total WOMAC, physical function, and stiffness subscores; patient and physician global
assessments of disease activity, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis
Research Society International (OMERACTeOARSI) strict responders, as well as safety of Gel-200.
Results: Of 379 patients randomized, safety was evaluated in 377 and efﬁcacy in 375 (98.9% randomized)
in the intent-to-treat population. Effectiveness of Gel-200 by WOMAC pain subscores was statistically
signiﬁcant at week 13 (P¼ 0.037). Mean improvements from baseline in WOMAC pain subscores
consistently favored Gel-200 at each visit. Effectiveness of Gel-200 treatment was statistically signiﬁcant
over weeks 3e13 by WOMAC total score, physical function, and physician global evaluations (P< 0.05).
The number of “strict” OMERACTeOARSI responders was statistically signiﬁcant from weeks 6 to 13
(P¼ 0.022). Adverse events were not signiﬁcantly different between treatment groups, including serious
adverse events considered related to study treatment.
Conclusions: This trial demonstrated that a single injection of Gel-200 was well tolerated and relieved
pain associated with symptomatic OA of the knee over 13 weeks.
Trial registration number: ClinicalTrials.gov NTC 00449696.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common arthritic condition and
among the more frequent and symptomatic health problems for
individuals 50 years of age1. Symptomatic OA of the knee is
a common presenting problem and its treatment can be frustrating
for patients and physicians2. Intra-articular hyaluronic acid (IA-HA)
injections of the knee have been demonstrated to reduce pain in
subjects with OA3,4. Treatment guidelines for OA recommend IA-HAto: H. Hosokawa, Clinical
6-1, Marunouchi 1-chome
950.
jp (H. Hosokawa).
s Research Society International. Pas useful therapeutic agents. However, a meta-analysis reported no
evidence of improvement in function or clinically meaningful
improvements in pain in placebo-controlled studies5. Five IA-HA
products are currently available for use in the United States,
requiring a series of 3e5 injections, as well as a recently approved
larger volume single injection product6,7. Newer cross-linked IA-HA
formulations have been designed to offer longer term beneﬁt
following a single injection. Such a single injection product would
be more convenient for patients and expected to be less invasive
thus reducing the potential risk of joint infections or hypersensi-
tivity reactions.
Gel-200 is a sterile, transparent, viscoelastic hydrogel composed
of cross-linked hyaluronate8, a derivative of a highly puriﬁedublished by Elsevier Ltd. All rights reserved.
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cross-linked HA diffuses out of the synovial ﬂuid rapidly after
administration into the knee joint, while injected Gel-200 was
found to persist in synovial ﬂuid for up to 7 days and synovium for
as long as 28 days in rabbits without IA inﬂammation9. The effects
of a single injection of Gel-200 have been compared with phos-
phate buffered saline (PBS) in an established experimental animal
model of OA: unilateral transection of the anterior cruciate liga-
ment (ACL) in rabbits1014. In comparison with PBS, a single
injection of Gel-200 signiﬁcantly decreased articular cartilage
degeneration at 9 weeks after ACL transection and was more
effective than ﬁve injections of non-cross-linked HA in the rabbit
model. In rats with arthritis pain induced by bradykinin and silver
nitrate, pain scores with Gel-200 administration were lower than
those administered PBS or non-cross-linked HA5,9,15. Additionally,
Gel-200 exhibited a longer analgesic effect compared with PBS in
a monosodium urate induced joint inﬂammation model in dogs16.
Based on these observations in pre-clinical animal studies, it was
expected that a single injection of Gel-200 would provide more
prolonged beneﬁt than multiple injection IA-HA products. This
report summarizes the results from a randomized controlled trial
(RCT) comparing the safety and effectiveness of a single injection of
Gel-200 vs PBS (control) in subjects with symptomatic OA of the
knee over 13 weeks.
Methods
Study design
This was a double-blind, multi-center RCT examining the safety
and effectiveness of a single injection of Gel-200, a new cross-
linked IA-HA product (Gel-One, Seikagaku Corporation, Tokyo,Fig. 1. Flow chart of paJapan) vs PBS (control) for treatment of symptomatic OA of the
knee. It was conducted from August 2006 to December 2007 (last
patient visit) at 28 sites in the US in accordance with good clinical
practices by International Conference on Harmonization guidelines
and in conformity with the Declaration of Helsinki. A central
Institutional Review Board (IRB) granted approval for the study and
patients were provided a written informed consent form approved
by the central IRB prior to enrollment. This study was registered
with ClinicalTrials.gov (identiﬁcation number: NTC 00449696).
A central randomization system was used to assign patients to
receive an IA injection of either Gel-200 or PBS in a 2:1 ratio
favoring Gel-200. An Interactive Voice Response System (IVRS)
provided sequential treatment assignments. An unblinded
“injecting physician” aspirated the knee if an effusion was present
and then injected either treatment, packaged identically, taking
appropriate measures to mask the treatment identity from the
subject using a visual screening device. To maintain blinding of
physician evaluations, a separate blinded “evaluating physician”
performed all evaluations pre-injection and at all post-injection
visits.
Treatment
Screening was performed 1e2 weeks prior to randomization.
Following aspiration of synovial ﬂuid if an effusion was present,
patients received a single IA injectionofGel-200 (30 mgcross-linked
HA in 3.0 mL) or PBS (3.0 mL) at week 0. Follow-up visits assessed
safety and clinical beneﬁt at weeks 1, 3, 6, 9 and 13 after injection.
Acetaminophen up to 4,000 mg/day was provided as rescue medi-
cation except within 24 h of a treatment evaluation. Non-steroidal
anti-inﬂammatory drugs (NSAIDs), nonprescription herbal thera-
pies and chondroprotective agents (e.g., oral HA, glucosamine,tient disposition.
Table I
Patient demographics and baseline disease characteristics
Parameter Gel-200 (n¼ 247) PBS (n¼ 128)
Gender
Male 100 (40.5%) 51 (39.8%)
Female 147 (59.5%) 77 (60.2%)
Age, years (mean SD) 60.9 10.24 60.3 9.97
Body mass index, kg/m2 (mean SD) 28.3 4.14 28.7 3.83
Study knee
Right 136 (55.1%) 62 (48.4%)
Left 111 (44.9%) 66 (51.6%)
KeL X-ray scores
(Grade 1) 21 (8.5%) 18 (14.1%)
(Grade 2) 94 (38.1%) 47 (36.7%)
(Grade 3) 132 (53.4%) 63 (49.2%)
Duration of OA in study knee
Months (mean SD) 42.0 51.4 31.2 41.2
WOMAC pain subscore 70.7 14.42 68.0 13.05
Total WOMAC score 69.5 15.99 67.8 14.68
WOMAC physical function subscore 68.9 17.41 67.6 15.80
WOMAC stiffness subscore 71.6 17.48 69.3 17.31
No statistically signiﬁcant differences were identiﬁed between treatment groups.
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change their treatment regimen and continued regular administra-
tion at stable doses from4 weeks prior to randomization throughout
protocol participation. Intermittent use of short-acting oral opiates
was also allowed. Use of anymedications for symptomatic pain relief
was prohibited within 24 h prior to each visit evaluation. Physical
therapy was prohibited throughout the study.
Protocol population
Patients were 40e80 years of age, with knee OA, and pain in the
affected knee of 4 weeks in duration while standing or walking;
KellgreneLawrence (KeL) grade 1e3 by X-ray; Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) pain
subscores 40 mm in affected knee and 20 mm in contralateral
knee by 100-mm Visual Analog Scale (VAS); and willing to dis-
continue current OA treatments other than allowed medications,
stable for 4 weeks prior to entry. Patients were excluded from
study participation for the following: KeL grade 4 of the treated
knee, inﬂammatory diseases of the knee other than OA, severe knee
joint effusion, severe malalignment of the knee, history of joint
replacement of knee or hip within the previous 12 months,Fig. 2. Improvements from baseline in WOMAC pain subscores.arthroscopy of either knee within 3 months, IA injections with
corticosteroids within the past 4 weeks, IA-HA injections within
the past 6 months, and/or serious systemic diseases or infectious/
inﬂammatory skin diseases in the area of the affected knee.Outcome measures
The primary outcome measure of effectiveness was patient-
reported WOMAC pain subscores by VAS in the affected knee at
week 13. Secondary outcome measures included Outcome
Measures in Rheumatology Clinical Trials and Osteoarthritis
Research Society International (OMERACTeOARSI) “strict”
responses1719: deﬁned by improvements from baseline in
WOMAC pain or physical function subscores 50% with absolute
changes 20 mm (termed “strict responders”) or 20% with
absolute changes 10 mm in two of three measures: WOMAC pain
or physical function subscores; and/or patient global assessments
of disease activity (termed “responders”). Mean changes from
baseline in total WOMAC, physical function and stiffness subscores,
patient and physician global assessments of disease activity by VAS,
and acetaminophen consumption, were recorded at each visit.
Medical Outcomes Survey Short-Form 36 (SF-36) for assessment of
health related quality of life was collected at weeks 0 and 13. The
percentage of patients reporting improvements meeting or
exceeding minimum clinically important differences (MCID) e.g.,
10 mm in WOMAC pain subscores, and/or “moderate” and
“substantial” changes deﬁned as 30% and 50%, respectively, by
the Initiative on Methods, Measurement, and Pain Assessment in
Clinical Trials (IMMPACT) working group were deﬁned in an
exploratory analysis2023. Times to response post injection
(1e13 weeks) were also assessed. Safety evaluations included
adverse events (AEs) coded by Medical Dictionary for Regulatory
Activities (MedDRAVer. 10.0) and examination of the affected knee
for swelling, redness or effusion at each visit following injection.
Hematology and serum chemistries were assessed at screening and
week 13. Any adverse signs and symptoms or clinically signiﬁcant
laboratory abnormalities were collected as AEs during the study.
Blinded investigators evaluated the severity of reported AEs and
their potential relationship with treatment.Statistical methods
Sample size calculations of 375 patients were determined based
on the following assumptions: (1) two-sided t-test, (2) 90% power,
(3) 5% signiﬁcance level, (4) 2:1 randomization allocation in favor of
Gel-200, (5) 10 mm detectable difference on a 100 mm VAS
WOMAC pain subscore, (6) standard deviation (SD) of 25 mm for
Gel-200 and 27 mm for PBS, and (7) an allowed 10% dropout rate
per group.
Analyses of effectiveness were performed in the intent-
to-treat (ITT) population, deﬁned as all randomized patientsTable IIa
Mean improvements from baseline in WOMAC pain subscores; Gel-200 vs PBS
Week Estimated difference
[95% conﬁdence
interval (CI)]
P-value Mean improvement
from baseline
Week 3 8.12 (3.47, 12.78) 0.001 40.6%
Week 6 8.12 (2.73, 13.50) 0.003 44.1%
Week 9 5.77 (0.26, 11.29) 0.040 44.8%
Week 13 6.39 (0.37, 12.41) 0.037 39.3%
Weeks 3e13 7.10 (2.15, 12.05) 0.005 e
Analyses used the primary model and tested the model-estimated difference
between two groups.
Table IIb
Effectiveness results at week 13 and over weeks 3e13
Measurements At week 13* Over weeks 3e13y
Estimated difference (95% CI) P-value Estimated difference (95% CI) P-value
WOMAC pain subscores 6.39 (0.37, 12.41) 0.037 6.31 (1.11, 11.51) 0.018
Total WOMAC score 5.64 (0.20, 11.47) 0.058 5.59 (0.41, 10.78) 0.035
WOMAC physical function subscores 5.42 (0.47, 11.31) 0.071 5.29 (0.02, 10.55) 0.049
WOMAC stiffness subscores 4.91 (1.31, 11.14) 0.122 5.27 (0.14, 10.69) 0.056
Physician global assessment 3.56 (1.48, 8.60) 0.166 5.97 (1.34, 10.59) 0.012
Patient global assessment 0.92 (4.63, 6.47) 0.746 3.82 (1.44, 9.09) 0.154
* Analyses used the primary model and tested the model-estimated difference between two groups.
y Additional exploratory longitudinal models assessed mean differences over weeks 3e13.
Table III
Summary of OMERACTeOARSI responders
Responder [n (%)] OR* in weeks 6 through 13
(Gel-200 e PBS)
Gel-200 (n¼ 247) PBS (n¼ 128) Estimate (95% CI) P-value
Strict OMERACTeOARSI responders
Week 6 120 (51.1%) 49 (39.5%) 1.59 (1.07, 2.37) 0.022
Week 9 125 (54.1%) 55 (46.6%)
Week 13 106 (45.9%) 46 (38.7%)
OMERACTeOARSI responders
Week 6 155 (66.0%) 76 (61.3%) 1.27 (0.85, 1.90) 0.242
Week 9 151 (65.4%) 74 (62.7%)
Week 13 141 (61.0%) 65 (54.6%)
* When odds ratio >1, then in favor of Gel-200.
V. Strand et al. / Osteoarthritis and Cartilage 20 (2012) 350e356 353who received treatment with at least one post-injection visit.
Improvement from baseline in WOMAC pain subscores was used
in the primary model, which tested the superiority of Gel-200
treatment using all available data through week 13, accommo-
dating a change in slope of VAS pain response at week 6. The
difference between the two groups in model-estimated
improvement from baseline at week 13 was the prospectively
deﬁned primary endpoint which tested the superiority of the
treatment using two-sided 95% lower bounds exceeding 0 mm for
Gel-200 e PBS. Secondary outcome measures supporting the
effectiveness of Gel-200 utilized the same models. The actual and
model-estimated differences between the two groups in changes
from baseline at weeks 3, 6, 9 and over weeks 3 through 13 were
calculated as well. Additional exploratory longitudinal models
assessed the superiority of Gel-200 for continuous endpoints
using least squares mean differences between groups in mean
changes from baseline between weeks 3 and 13 in all
major outcome measures. OMERACTeOARSI responders/strict
responders were similarly compared between treatment groups
across weeks 6 and 13 using a generalized estimating equation
(GEE) regression model.
Safety analyses included all patients who received treatment. All
P-values were based on two-sided tests to compare Gel-200 with
PBS treatment with P¼ 0.05 used as a threshold for statistical
signiﬁcance.
Results
Patient population
A total of 598 patients were screened; 379 patients met eligi-
bility criteria and were randomized to treatment; 377 patients
were analyzed for safety; 375 patients comprised the pre-deﬁned
ITT population, having received IA injection of study drug, with
one post baseline assessment. Of 375 patients in the ITT pop-
ulation, 247 received Gel-200 and 128, PBS; 350 patients (92.3%)
completed the study (Fig. 1). Patient demographics and baseline
disease characteristics were comparable between treatment
groups (Table I).
Effectiveness measures
Mean changes from baseline in WOMAC pain subscores
demonstrated a statistically signiﬁcant advantage of 6.39 mm for
Gel-200 treatment over PBS at week 13 (P¼ 0.037; Fig. 2 and
Table IIa). Treatment differences at weeks 3 and 6 exceeded 8 mm
(P¼ 0.001 and P¼ 0.003, respectively), and the overall difference
over weeks 3 through 13 was 7.10 mm (P¼ 0.005). Mean
improvements from baseline in WOMAC pain subscores consis-
tently favored Gel-200 at each visit, with improvements of 40.6% at
week 3 and 44.1% at week 6. Effectiveness in the Gel-200 treatedgroup was sustained over weeks 3e13 by WOMAC total score,
physical function, and physician global evaluations with statistical
signiﬁcance (P< 0.05, Table IIb) in addition to WOMAC pain. In the
ITT population, the odds ratio (OR) for “strict” OMERACTeOARSI
responders was statistically signiﬁcant for Gel-200 vs PBS from
weeks 6 to 13 [OR¼ 1.59; P¼ 0.022; Table III and Fig. 3(a)]. There
were no statistically signiﬁcant differences in SF-36 betweenweeks
0 and 13, although beneﬁt was demonstrated in both treatment
groups.
In terms of clinically meaningful responses over weeks 3e13,
64.5e72.8% of patients reported improvements MCID in Gel-200;
compared with 57.1e69.5% in PBS, moderate improvements 30%
in a maximum of 62.1% vs 54.0% at week 6 and substantial
improvements 50% in a maximum of 49.4% vs 37.9% at week 6
(Fig. 3).
Safety measures
The safety proﬁle following a single Gel-200 injection was
comparable to PBS over 13 weeks; reported AEs are shown in
Table IVa. The incidence of AEs was similar in both treatment
groups; 182 treatment-related AEs were reported in 100 patients:
67 (26.9%) in Gel-200 and 33 patients (25.8%) in PBS groups,
respectively. Most common treatment-related AEs included joint
swelling, effusions and arthralgia, without signiﬁcant differences
between treatment groups. Serious adverse events (SAEs) were
reported in eight patients, including ﬁve cases of cancer (Table IVb).
Nonewere judged by investigators to be related to study treatment,
although all SAEs occurred in the Gel-200 group, including one
death. No clinically notable changes in laboratory results were
identiﬁed.
Discussion
This RCT compared treatment with a single IA injection of Gel-
200 with PBS over 13 weeks in patients with symptomatic OA of
the knee. Onset of effectiveness of Gel-200 was evident by week 3
Fig. 3. OMERACTeOARSI strict responders and patients reporting improvements 10 mm (MCID), 30%, 50% in WOMAC pain subscores.
Table IVa
AEs overview
Gel-200 (n¼ 249) PBS (n¼ 128)
Patients
[n (%)]
Events
(n)
Patients
[n (%)]
Events
(n)
Total AEs 172 (69.1%) 483 81 (63.3%) 216
SAEs 8 (3.2%) 19 0 0
Unanticipated related
adverse events
0 0 0 0
Total related AEs 67 (26.9%) 124 33 (25.8%) 58
Related AEs occurring
within 24 h of IA injection
35 (14.1%) 43 14 (10.9%) 19
Related AEs occurring in 5%
Joint swelling 35 (14.1%) 43 15 (11.7%) 18
Joint effusion 28 (11.2%) 31 13 (10.2%) 13
Arthralgia 19 (7.6%) 24 12 (9.4%) 14
No statistically signiﬁcant difference was identiﬁed between treatment groups.
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signiﬁcant improvements in WOMAC pain subscores at study
endpoint, week 13, the primary outcome measure, and over weeks
3e13. These advantages were further demonstrated by strict
OMERACTeOARSI responders, including subjects reporting
“moderate” e.g., 30% and “substantial” e.g., 50% changes from
baseline in WOMAC pain subscores also exceeding MCID.
Improvements in total WOMAC scores, WOMAC physical function
and physician global assessments of disease activity over weeks
3e13 further support the efﬁcacy of Gel-200 treatment; a lesser
degree of improvement was observed for patient global assessment
of disease activity. Mean improvements in WOMAC pain subscores
with Gel-200 exceeded 20 mm and were consistently better than
PBS treatment throughout end of study week 13 reaching
a maximum of 31.7 mm. Subjects in the Gel-200 treatment group
reported at least 40% mean improvement from baseline in WOMAC
pain subscores at each post-injection visit.
This study prospectively enrolled patients with KeL grade 1e3
to be consistent with several other pivotal studies for this indica-
tion. Our inclusion criteria further required both knee pain for at
least 4 weeks and radiographic evidence of tibio-femoral osteo-
phytes, osteosclerosis of the femoral or tibial endplates, or joint
space narrowing. Patients also were required to have 40 mm in
WOMAC pain subscore at the screening visit. Hart and Spector
reported that KeL grade 1 patients beneﬁtted from early inter-
vention24. This PBS-controlled randomized study established Gel-
200 effectiveness in OA patients meeting these prospective criteria.
When comparing differences in mean changes from baseline in
WOMAC pain subscores between Gel-200 treatment and PBS,
a statistically signiﬁcant advantage of 8.12 mm was evident by
week 3 and sustained through end of study week 13 at 6.39 mm. In
contrast to other IA-HA injections25,26, Gel-200 demonstrated
earlier onset of beneﬁt. Despite meta-analysis reporting large
placebo effects in studies examining treatment with IA-HAinjections in OA of the knee27,28, a single injection of Gel-200
demonstrated treatment advantages over control (PBS) compa-
rable to other OA therapies, including oral NSAIDs29.
Although few trials of IA-HA products have reported a statisti-
cally signiﬁcant effect on physical function30,31, Gel-200 treatment
resulted in absolute mean changes exceeding 20 mm in WOMAC
physical function subscores over weeks 3e13, reﬂecting 30%
improvements at each post-injection visit. Strict OMERACTeOARSI
responses requiring 50% improvements in this trial were evident
as soon as 6 weeks following injection as were clinically mean-
ingful changes from baseline in both WOMAC pain and physical
function subscores over weeks 3 through 13; 62% of patients
reported 30% pain relief, and approximately 50% of patients
reported 50% pain relief. On the other hand, there was no statis-
tically signiﬁcant difference between Gel-200 and PBS groups in
patient global assessment of disease activity. However, the
Table IVb
List of SAEs
No. Gender Age Treatment SAE Days post injection Device related Anticipated
1 Female 65 Gel-200 Ductal carcinoma (Right breast) 16 No No
2 Female 67 Gel-200 Cardiac arrest 76 No No
Respiratory arrest 76 No No
Cryptogenic cirrhosis 76 No No
Acute bilateral pulmonary edema 77 No No
Respiratory failure 85 No No
Acute renal failure 87 No No
Hypokalemia 87 No No
3 Female 49 Gel-200 Transient ischemic attack 78 No No
4 Female 75 Gel-200 Exertional dyspnea 41 No No
Transient blurry vision 41 No No
Dizziness 41 No No
5 Female 43 Gel-200 Incarcerated right femoral hernia 33 No No
Abdominal pain left side 39 No No
Abdominal pain 51 No No
6 Male 76 Gel-200 Basal cell carcinoma of the face (left eyelid and cheek) 45 No No
Malignant melanoma 45 No No
7 Male 80 Gel-200 Prostate cancer 56 No No
8 Male 78 Gel-200 Squamous cell carcinoma 74 No No
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meaningful improvements in WOMAC pain and physical function
scores, and in statistically signiﬁcantly more strict OMERACT/OARSI
responders.
Eight cases of SAEs were reported in the Gel-200 group; all
judged unrelated to study treatment, including ﬁve cancers diag-
nosed soon after treatment administration. These are consistent
with the age of the study population and neither their timing of
occurrence nor pre-clinical data would suggest a plausible rela-
tionship to administration of Gel-20032,33. In pre-clinical studies,
Gel-200 was not shown to be associated with carcinogenicity. AE
rates were generally comparable between treatments. No unan-
ticipated treatment-related AEs were reported. As might be
expected, the most common treatment-related AEs were joint
swelling, joint effusion and arthralgia, frequently reported in other
IA-HA studies29. Importantly, pseudosepsis, an AE associated with
another cross-linked IA-HA product, hylan G-F 203436, and allergic
reactions were not reported in the 249 patients receiving Gel-200
in this trial. Results are subject to further studies which would
enlarge the patient population receiving Gel-200.
Together these results indicate that treatment with Gel-200
offers statistically signiﬁcant and clinically meaningful improve-
ments both in pain and physical function, of early onset, in patients
with knee OA, thereby demonstrating the multi-dimensional
effectiveness of this therapy. The absence of allergic reactions or
‘pseudosepsis’ and the low incidence of treatment associated AEs
support a favorable safety proﬁle for this cross-linked IA-HA
product for treatment of symptomatic OA of the knee.
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